Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes

Breast Cancer Research and Treatment
Qijia XuanQingyuan Zhang

Abstract

Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target in breast cancer. However, not all patients benefit from trastuzumab-based therapy. We aimed to investigate whether patients with different levels of HER2 amplification would experience different clinical outcomes with trastuzumab-based chemotherapy. We quantified the HER2 gene copy number (GCN) and HER2/centromere chromosome probe 17 (CEP17) ratio in 291 breast cancer patients with HER2 amplification confirmed by immunohistochemistry and fluorescence in situ hybridization. The optimal cutoff points for HER2 GCN and the HER2/CEP17 ratios for distinguishing positive results were determined by receiver operating characteristic (ROC) curve analyses. ROC analysis identified optimal cutoff points for HER2 GCN and HER2/CEP17 ratios as 11.5 and 6.5 (P = 0.039 and P = 0.012), respectively. The DFS in patients with HER2 GCN <11.5 was significantly longer than in HER2 GCN ≥11.5 patients (P = 0.015) according to Kaplan-Meier survival curves analysis. Similarly, patients with HER2/CEP17 ratios <6.5 had a significantly longer DFS than those with HER2/CEP17 ratios ≥6.5 (P = 0.013). Moreover, patients with HER2 cluster amplification showed a worse survival than...Continue Reading

References

Feb 19, 2002·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sijian WangRaheela Ashfaq
Aug 5, 2004·Journal of the National Cancer Institute·Gottfried E KonecnyDennis J Slamon
Jan 1, 1950·Cancer·W J YOUDEN
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roman RouzierLajos Pusztai
Jan 26, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rosa GiulianiFatima Cardoso
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laurent ArnouldBruno P Coudert
Feb 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BatesA Lipton
Mar 6, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Hyesil SeolSo Yeon Park
Mar 12, 2013·The Breast : Official Journal of the European Society of Mastology·Giuseppe GulloArmando Santoro
Oct 2, 2013·Cancer Treatment Reviews·Iben KümlerDorte Lisbet Nielsen
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Oct 12, 2013·CA: a Cancer Journal for Clinicians·Carol DeSantisAhmedin Jemal
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlos Gomez-MartinFernando Lopez-Rios
Feb 11, 2014·Advances in Anatomic Pathology·Uma Krishnamurti, Jan F Silverman
Jul 19, 2014·The Breast : Official Journal of the European Society of Mastology·Michael UntchGunter von Minckwitz
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Jan 7, 2015·Global Journal of Health Science·Ali AboutorabiMaryam Ghiasipour

❮ Previous
Next ❯

Citations

Jun 16, 2015·PloS One·Rocio VicarioJoaquín Arribas
Jun 21, 2017·International Journal of Molecular Sciences·Xingjuan ShiMin Liu
May 22, 2018·Frontiers in Oncology·Azadeh NasrazadaniAdrian V Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.